Purpose The aim of this study was to evaluate the relationship between semiquantitative parameters on 18 F-FDG PET/CT including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) and the expression level of Ki-67 in small-cell lung cancer (SCLC). Methods Ninety-four consecutive patients with SCLC were enrolled in this study. They underwent 
Introduction
Lung cancer accounts for 12 % of all new cancer cases and is the second most common cancer in men and women worldwide [1] . Lung cancer is the leading cause of cancer-related death in the USA and the Republic of Korea. Small-cell lung cancer (SCLC) represents 13 % of all newly diagnosed cases of lung cancer worldwide or more than 180,000 cases per year [1, 2] . SCLC generally has a more rapid doubling time, higher growth fraction, and earlier development of widespread metastases compared with those of non-small-cell lung cancer (NSCLC), all of which lead to frequent relapse and a poor prognosis, despite high sensitivity to initial chemotherapy and radiotherapy [1, 3] . Understanding the biological characteristics of this devastating disease could facilitate early diagnosis and individualized treatment and improve the survival rate.
Uncontrolled cell proliferation is a key characteristic of cancer. Some studies have demonstrated that the expression level of Ki-67, an indicator of cell proliferative activity, is an important prognostic factor in various cancers [4] [5] [6] including lung cancer [7] . However, molecular markers can only be tested in vitro after tissue has been removed from the patient, and surgical or pathological sampling errors can occur. Therefore, imaging cellular proliferation may be an alternative approach to diagnosing and staging malignancies.
Positron emission tomography/computed tomography (PET/CT) using the tracer 18 F-fluorodeoxyglucose ( 18 F-FDG) has emerged as an essential oncological imaging tool for diagnosing, staging, restaging, and determining treatment response [8] . The standardized uptake value (SUV), which is the most popular semiquantitative parameter to objectify PET/CT data, reflects the glucose metabolic rate and is used to characterize tumor metabolism in vivo. Metabolic tumor volume (MTV), defined as the volume of tumor tissue with increased 18 F-FDG uptake, and total lesion glycolysis (TLG), defined as the product of MTV and mean SUV (SUVmean), are also important independent prognostic factors in various cancers [9] [10] [11] [12] . The degree of 18 F-FDG tumor uptake on PET/CT as measured by SUV is correlated with cell proliferative activity as determined by the Ki-67 expression level in patients with NSCLC [13] [14] [15] . However, it remains unclear whether macroscopic functional imaging techniques correlate with microscopic predictive molecular markers in patients with SCLC.
In this study, we evaluated the degree of 18 F-FDG uptake on PET/CT imaging in combination with immunohistochemical results and found potential correlations among the maximum SUV (SUVmax), SUVmean, MTV, TLG, and Ki-67 expression level in patients with SCLC. We also tried to understand the underlying biological mechanisms of FDG uptake in patients with SCLC.
Materials and Methods

Patients
We retrospectively reviewed 145 patients with histologically or cytologically proven SCLC who underwent a pretreatment Cleveland, OH, USA). All patients fasted for at least 6 h and had serum glucose levels<140 mg/d before the scan. CT scans were obtained followed by PET scans for 1 min/ bed 1 h after an intravenous injection of 370-555 MBq 18 F-FDG according to body weight. This PET unit had an 18-cm axial field of view and 4.4-mm spatial resolution. A low-dose CT scan was obtained for attenuation correction and localization on a 16-slice multidetector helical CT unit using the following parameters: 120 kVp; 50 mA; 0.75-s rotation time; 0.75-mm slice collimation; 4-mm scan reconstruction, with a reconstruction index of 4 mm; 50-cm field of view; 512×512 matrices. The PET data were reconstructed iteratively following CT using a three-dimensional row action maximum likelihood algorithm with low-dose CT data sets used to correct attenuation. Maximum intensity projection, cross-sectional views, and fusion images were reviewed.
Image Interpretation and Quantitation
All images were interpreted and analyzed by two experienced nuclear medicine physicians on a dedicated workstation (Extended Brilliance Workspace 4.0 with a PET/CT viewer for automated image registration, Philips, Amsterdam, The Netherlands). We used all available clinical information, reviewed it together, and interpreted the PET/CT images by consensus.
We defined a malignant lesion as one that showed relatively increased metabolism compared to the metabolism of adjacent normal tissues and that was not clearly associated with normal structures.
We measured the SUV of malignant lesions by drawing a region of interest (ROI) for the semiquantitative analysis. The ROI was placed over the area of maximum activity within the malignant lesion, and the SUVmax was determined as the highest SUV of the pixels within the ROI.
We also measured the MTVs of each lesion using a semiautomatic method to delineate the volume of interest over the malignant lesion (Fig. 1) . We chose the most intense point on each malignant lesion and drew the lesion boundaries using SUV-based contouring software. A fixed 50 % of local maximum intensity was used as the threshold intensity value, and this was deemed reasonable from previous studies [16] [17] [18] . When the automated software included not only malignant lesions but also background activity, we manually removed the background boundaries by reviewing the background CT findings. We calculated the sum of MTVs of all malignant lesions (MTVsum) by adding all MTVs of each lesion. The program also analyzed the SUVmean of each lesion, and we calculated the avgSUVmean by averaging all SUVmeans of each lesion. The TLGtotal value was calculated by multiplying MTVsum by avgSUVmean.
Ki-67 Immunohistochemical Staining and Evaluation
Formalin-fixed, paraffin-embedded biopsy specimens were cut 4 μm thick and taken for immunohistochemical staining with the MIB-1 antibody (Dako, Glostrup, Denmark), which was a monoclonal murine antibody specific for human nuclear antigen Ki-67 and used as a primary antibody in a 1:200 dilution.
The percentages of Ki-67-positive cells were evaluated at×400 magnification, by counting distinctly stained nuclei per 1000 tumor cells in the most representative area, which, in most instances, corresponded to areas with the highest mitotic activity. Then the Ki-67 results were categorized into ten groups at 10 % intervals.
The histopathological slides were examined by an experienced pathologist.
Statistical Analysis
Statistical analyses were performed using SPSS version 18.0 software (SPSS Inc., Chicago, IL, USA). A P-value<0.05 was considered significant. Two-sided correlations between SUVmax, avgSUVmean, MTVsum, and TLGtotal and the percentages of cells immunostained for Ki-67 were analyzed with Spearman's rank correlation coefficient. The Ki-67 expression level was divided into three categories of≤30 % positive tumor cells, 30-60 % positive tumor cells, and>60 % positive tumor cells, based on a previous report [19] . The PET/CT parameters of each category were compared using the Jonckheere-Terpstra test. 
Results
Patient Characteristics
Twenty-seven patients were excluded because of the absence of Ki-67 immunohistochemical staining data. Ten patients who were treated with chemotherapy or radiotherapy before the 18 F-FDG PET/CT scan, five who had brain metastases, five who had another primary malignancy, and four whose 18 F-FDG PET/CT scan imaging data were insufficient were also excluded. Finally, 94 patients were enrolled in this study.
The characteristics of the 94 patients with SCLC are summarized in Table 1 . Mean age was 67.17 (±8.7 years). Fortyfour patients (46.81 %) had limited disease, and 50 patients (53.19 %) had extensive disease.
Correlations between PET/CT Parameters and Ki-67 Staining
SUVmax, avgSUVmean, MTVsum, and TLGtotal, and the percentages of Ki-67-positive cells in tumor tissues were analyzed (Fig. 2) . No correlation was found between SUVmax and Ki-67 expression (Spearman's r=0.116, p=0.264) or between avgSUVmean and Ki-67 expression (r=0.031, p= 0.770). Significant correlations were found between MTVsum and Ki-67 expression (r = 0.254, p = 0.014) and between TLGtotal and Ki-67 expression (r = 0.239, p = 0.020). In Fig. 2 , there are three outliers in the MTV at the high Ki-67 categories (60-100 %). The data were further analyzed, except the three biggiest outliers, and significant correlation was still present between MTVsum and Ki-67 expression (r=0.208, p=0.049).
Analyses between the PET/CT parameters and Ki-67 expression levels divided into three categories are summarized in Table 2 . Increasing Ki-67 expression level increased the MTVsum and TLGtotal stepwise (p=0.028 and 0.039, respectively, Jonckheere-Terpstra test), but not the SUVmax or avgSUVmean (p=0.526 and 0.729, respectively).
Discussion
Ki-67 is widely considered a cell proliferation marker and is mainly expressed during the active phases of the cell cycle, i.e., G1, S, G2, and mitosis [20] . A high cell proliferation rate is a hallmark of cancer, and high Ki-67 expression predicts poor survival in patients with multiple myeloma, prostate cancer, and breast cancer [4] [5] [6] . Some studies have revealed that glioma, bladder cancer, and anal cancer with high Ki-67 positivity are more aggressive and invasive [21] [22] [23] . A metaanalysis reported that the Ki-67 labeling index has prognostic significance in patients with NSCLC and that a high index suggests a poor prognosis [24] . A correlation between cell metabolic activity as determined by 18 F-FDG PET/CT SUV and cell proliferative activity as determined by the Ki-67 expression level has been suggested by some studies on NSCLC [13] [14] [15] .
In contrast to studies on other malignancies, there have been few studies about the impact of Ki-67 in SCLC and no studies considering the correlation between the volumetric parameters of 18 F-FDG PET/CT and the Ki-67 proliferation index in patients with SCLC. This may be due to the difficulty obtaining sufficient and adequate tumor material. SCLC is not a candidate for surgical resection, and only a small specimen is available to investigate biologic markers in most patients. Information from a single biopsy may not reflect the true picture of the entire tumor. Furthermore, SCLC tissue is often crushed with crushed nuclei; thus, an evaluation of nuclear markers may be difficult. About 20 % of our patients (27 patients) were excluded because no Ki-67 immunohistochemical staining data were available because of inadequate specimens. Consequentially, it is difficult to use the Ki-67 labeling index as a prognostic biomarker to comprehensively characterize an individual tumor before SCLC treatment. 18 F-FDG PET/CT compensates for this to some extent because it noninvasively and reproducibly identifies tumor biological characteristics in vivo. 18 F-FDG PET/CT avoids unnecessary diagnostic biopsies of malignant lesions and permits serial assessments during cancer therapy. Therefore, many investigations have evaluated tumor proliferation noninvasively using 18 F-FDG PET/CT [13, 14, 15, [25] [26] [27] [28] [29] [30] . In addition to its noninvasiveness, 18 permits an evaluation of the entire tumor, overcoming issues of heterogeneity and tumor sampling errors. A high Ki-67 expression level has been reported to be associated with tumor size in breast cancer and NSCLC [31, 32] , indicating that a high proliferation rate is related to tumor volume. Indeed, in the present study, the MTVsum and TLGtotal, which reflect tumor metabolism and volume on 18 F-FDG PET/CT, were correlated with cell proliferative activity as determined by the Ki-67 labeling index, and even though the three biggest outliers were omitted, the MTVsum was correlated with cell proliferative activity. It has been difficult to quantify the total body tumor burden directly and systematically. Until now, tumor stage, which is the most important SCLC prognostic factor, and other prognostic factors, such as performance status, weight loss, and serum lactate dehydrogenase level, may simply be used as surrogates for the underlying tumor burden, which is a direct predictor of disease progression and survival [1] . CT-based tumor volume does not represent the actual tumor size or tumor burden because tumors are not always uniformly shaped and could contain a necrotic portion with nonviable tissues. Functional imaging provides metabolic and volumetric information, such as MTV, which represents the number of highly metabolic tumor cells, making it possible to more accurately reflect tumor burden than other prognostic factors. In SCLC, it has been reported that gross tumor volume 18 F-FDG PET/CT, as part of radiation treatment planning, and MTV and iSUV (product of MTV and SUVmean) predict prognosis [9, 18, 33] .
F-FDG PET/CT imaging
In contrast, SUVmax and avgSUVmean, which are commonly used objective 18 F-FDG PET/CT parameters, were not correlated with cell proliferative activity as determined by Ki-67 immunostaining. Although it seems that increased glucose metabolism produces sufficient energy for proliferation of tumors with high multiplication potential, FDG uptake only reflects part of cell proliferation. FDG uptake may originate from additional mechanisms, such as expression of glucose transporters, hexokinase, and glucose-6-phosphatase, tumor blood flow, viable tumor cell number, or tumor cell density rather than from cell proliferation alone. It is difficult to determine which particular factor plays a critical role in FDG uptake if the influences of other factors are not controlled. Further study will be needed to find the underlying mechanisms of FDG uptake in SCLC.
The glucose metabolism and biological characteristics of SCLC are complex and difficult to understand completely. Nevertheless, it is reasonable to hypothesize that 18 F-FDG PET/CT volumetric parameters, such as MTV and TLG, may be more effective for predicting clinicopathological characteristics and stratifying risk groups with the goal of developing individualized therapeutic strategies in patients with SCLC.
There are several limitations including the retrospective nature of the study design and relatively low number and heterogeneity of the patients. We excluded patients with brain metastasis because torso PET/CT scans were performed. However, PET/CT scans tend to be whole-body studies, allowing for a comprehensive assessment of whole-body tumor burden, except the brain. There were three cases of smallcell lung cancer with a low percentage of Ki-67 expression level (below 30 %) in the present study. Even though some studies showed a high Ki-67 percentage in small-cell lung cancers [34, 35] , other studies showed small-cell lung cancer cases with a low percentage of Ki-67-positive cells [36, 37] . Therefore, we considered the findings in the present study reliable. Another limitation is that a fixed 50 % of local maximum intensity was used as the threshold intensity value. The consensus for the cutoff value of the delineating tumor boundary is not yet established, and MTV can be affected by various threshold values. Despite these limitations, this report is noteworthy because it is the first study to show correlations between 18 F-FDG PET/CT volumetric parameters and the Ki-67 proliferation index in patients with SCLC.
Conclusion
Whether 18 F-FDG PET/CT can be combined with established predictive factors, such as clinicopathological characteristics, to assess SCLC tumor characteristics is an essential and practical issue worthy of investigation. Our results suggest that 18 F-FDG PET/CT MTVsum and TLGtotal are well correlated with the Ki-67 proliferation index in patients with SCLC. Further study will be performed to compare the volumetric PET parameters by various thresholds and evaluate their clinical significance in SCLC.
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